Stock Analysis
Gilead Sciences IncGILD
Sector: Healthcare · Industry: Biotechnology
AnalystsStrong Buy37 analystsPrice is 97% of the way from the year's low to its high.
Cash covers 0% of debt · FY 2025.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation52
- Profitability0
Weak fundamentals at a demanding price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 4.8 — safe-zone balance sheet
What's happening with GILD
Profile
Strong moat; profitability, growth and financial health lag behind.
How is each axis scored?
- Valuation52/100 · Moderate
- P/E vs own history (n/a)10/25
- FCF yield (6.7%)20/25
- P/S (6.4x)12/25
- EV/EBIT (n/a)10/25
- Growth30/100 · Weak
- Revenue CAGR (1.9%)6/25
- Net income CAGR (8.1%)12/25
- EPS CAGR 5Y (8.3%)12/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-4.1%)0/25
- ROE (-14.3%)0/25
- Net margin (-10.6%)0/25
- Operating margin (-8.2%)0/25
- Financial Health48/100 · Weak
- Altman Z (4.77)25/25
- Current ratio (1.55)18/25
- Interest coverage (-17.0x)0/25
- Net cash / debt (D/A 42%)5/25
- Quality50/100 · Moderate
- Piotroski F (8/9)25/25
- Beneish M (-2.55)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 26.9%)0/25
- Moat82/100 · Strong
- ROIC >12% years (8/10 yrs)20/25
- Median gross margin (79.0%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 0.5%)12/25
Risk Flags
- ⚠Interest coverage -17.0× — thin debt cushion
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Show more
Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Headquarters: FOSTER CITY, CA · Employees: 17,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
52CP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF15.5xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.7%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 4.7%–13.7% · 20th pct
P/S (TTM)6.39xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.7x–6.7x · 99th pct
EV/EBITDA20.2xC
Grade C: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales7.2xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E22.0xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio8.57xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.41D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield3.07%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio97.9%D
Grade D: UnsustainableDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-4.1%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-14.3%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-5.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-10.6%D
Grade D: LowNet Income / Revenue
Operating Margin-8.2%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin79.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin42.5%A
Grade A: HighFCF / Revenue
True FCF Margin39.5%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
30DRevenue CAGR1.9%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR8.1%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)8.3%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-1.7%B
Grade B: FlatShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue3.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
48D+Altman Z-Score4.77A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.55xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.75xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-17.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment1.9yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity1.10xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.00xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
50CPiotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.55A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability26.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue2.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.55xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
O'Day Daniel Patrick Filed | O'Day Daniel Patrick | SellOpen market sale | -3000 | |
O'Day Daniel Patrick Filed | O'Day Daniel Patrick | SellOpen market sale | -12000 | |
Burkhart Erin Filed | Burkhart Erin | Option exercise | -2223 | |
Burkhart Erin Filed | Burkhart Erin | Tax withholding | -768 | |
Burkhart Erin Filed | Burkhart Erin | Option exercise | +2.2K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mercier Johanna Filed | Mercier Johanna | SellOpen market sale | -600 | |
Mercier Johanna Filed | Mercier Johanna | SellOpen market sale | -800 | |
Mercier Johanna Filed | Mercier Johanna | SellOpen market sale | -1600 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
82AROIC >12% Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)79.0%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor0.5%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$2.56
Cash & short-term investments per share (Finnhub)
Book Value / Share$9.53
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$24.94B
Total debt obligations (short + long term)
Cash & Equiv.$68.00M
Cash and short-term investments
Net Debt$24.87B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$22.70B
Shareholders' equity (book value)
Asset / Liability1.63xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$194.47B
Current Market Capitalization
Beta0.40B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Gilead Sciences Inc (GILD)
GILD is down 0.75% at the last close. Gilead Sciences Inc meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 4.77 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.55 suggests a low likelihood of earnings manipulation.
- Gilead Sciences Inc converts about 42% of revenue into free cash flow — strong cash generation.
- Takes ~1.9 years to repay net debt from free cash flow.
- Interest coverage of -17.0× leaves little room for earnings shocks.
- The stock currently yields 3.1% in dividends.
See how GILD ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GILD moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 158.46 | +3.21% | 2.07 |
| Oct 14 | Regular | 153.10 | +3.50% | 2.65 |
| Oct 14 | After-hours | 154.60 | +4.52% | 3.41 |
| Oct 9 | Regular | 150.91 | +2.59% | 2.12 |
| Oct 9 | After-hours | 151.20 | +2.79% | 2.28 |
Frequently Asked Questions about GILD
What is the current Gilead Sciences Inc (GILD) stock price?
GILD is trading at $156.19 at the last market close, down 0.75% on the session. PreMarketPrice tracks GILD pre-market, intraday and after-hours prices.
Is GILD stock a buy right now?
PreMarketPrice's quantitative model rates Gilead Sciences Inc's financial health at 48/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is GILD stock overvalued?
Gilead Sciences Inc trades at a trailing P/E of n/a and our valuation score rates it 52/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Gilead Sciences Inc report earnings?
No confirmed earnings date is currently scheduled for GILD. The Earnings section lists recent reports and updates as dates are announced.
What sector does Gilead Sciences Inc operate in?
Gilead Sciences Inc operates in the Healthcare sector, within the Biotechnology industry. The Related Stocks section lists sector peers for comparison.
What does Gilead Sciences Inc do?
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
About Gilead Sciences Inc (GILD) Stock
Gilead Sciences Inc (GILD) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry. As of the latest update, Gilead Sciences Inc is trading at $156.19, down 0.75% on the day with a market capitalization of $194.5 billion. The financial health score for GILD is 48/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GILD stock.
GILD Stock Analysis & Key Metrics
On PreMarketPrice, you can track Gilead Sciences Inc (GILD) across multiple dimensions:
- Pre-market price & movement: Real-time GILD stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GILD with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Gilead Sciences Inc across multiple reporting periods.
- Financial health score: A composite score of 48/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GILD.
- Sector peers: Compare GILD against 6 other healthcare stocks on key financial metrics.
Is GILD a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Gilead Sciences Inc (GILD) as an investment. The financial health score of 48/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Gilead Sciences Inc (GILD) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.